Latest News
Thursday newspaper round-up: China deal, pension deficits, BT, Amazon
Chinese officials are open to launching trade negotiations with Britain in the aftermath of the Brexit vote, raising hopes that the UK’s economy can receive a boost after it leaves the EU. Critics of Brexit warned that the UK could find itself alone and cut off from the world economy outside the EU, but the indications from China are that deals are possible. - Telegraph.
Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Novartis International AG / Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
Novartis International AG / Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment.
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Novartis International AG / Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
Novartis International AG / New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Novartis International AG / Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.